GLP-1 receptor agonists that are prescribed once weekly, such as semaglutide, dulaglutide, and long-acting release exenatide, are inactive and half-way eliminated in 5 to 7 days.

These benefits not only make GLP-1 agonists effective for managing type 2 diabetes but also contribute to better cardiovascular health. However, the effect of GLP-1 agonists varies from one person ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.GLP-1 receptor agonists have demonstrated benefits in ...

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

GLP-1 receptor agonists improve outcomes in patients with coronary plaque and post-STEMI, reducing adverse cardiovascular events and hospitalizations. Patients using GLP-1s show higher event-free ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor users (HR 0.90, 95% CI 0.82-0.98).

Among 24,103 individuals dispensed a GLP-1 receptor agonist between 2012 and 2021, 8083 were dispensed antidepressants in 2022 (odds ratio, 1.52).

Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster ...